Abstract: The invention features compositions and methods for predicting endurance athletic performance.

Abstract: The invention features compositions and methods for inhibiting bone loss and arthritis.

Abstract: The invention provides methods for the treatment of coronary heart disease, peripheral vascular disease, stroke, and ischemia featuring agents that interfere with the expression or activity of Cthrc1. The invention also provides the use of Cthrc1 peptide as a therapeutic agent for the treatment of acute or chronic cardiac deficiencies. The invention further provides detection and monitoring of Cthrc1 peptide in blood or serum to assess or monitor cardiac function.

Abstract: The invention features compositions and methods for treating and preventing steatosis, osteoporosis, and muscle weakness featuring the receptor for the collagen triple helix repeat containing-1 (Cthrc1) protein.

Abstract: The present invention features compositions and methods for treating and preventing a metabolic syndrome featuring the collagen triple helix repeat containing-1 (Cthrc1) protein.

Abstract: The present invention features compositions and methods for treating and preventing a metabolic syndrome featuring the collagen triple helix repeat containing-1 (Cthrc1) protein.

Abstract: The invention provides methods for the treatment of coronary heart disease, peripheral vascular disease, stroke, and ischemia featuring agents that interfere with the expression or activity of Cthrc1. The invention also provides the use of Cthrc1 peptide as a therapeutic agent for the treatment of acute or chronic cardiac deficiencies. The invention further provides detection and monitoring of Cthrc1 peptide in blood or serum to assess or monitor cardiac function.

Abstract: The invention relates to a novel CTHRC1 nucleic acid and protein encoded thereby. Expression of CTHRC1 is induced by injury in, among others, arteries and skin, and CTHRC1 is expressed in bone, cartilage, kidney, lung and brain. CTHRC1 expression is associated with collagen matrix production, arterial remodeling, arterial restenosis, constrictive remodeling, vessel injury, ectopic ossification, fibrosis, and the like. CTHRC1 also plays a role in cell-cell and cell-matrix adhesion, cell-migration, and bone, cartilage, skin and brain development. CTHRC1 also regulates the level of BMPs, including BMP1 and BMP4, and the invention encompasses methods relating to affecting the level of BMPs by affecting the level of CTHRC1. In addition, the invention relates to modulation of the level of CTHRC1 to affect processes associated with fibrosis mediated by formation of collagen matrix.

Abstract: The invention relates to novel nucleic acids encoding a mammalian adventitia inducible and bone expressed gene designated REMODEL, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, negative remodeling, arterial restenosis, vessel injury, ectopic ossification, fibrosis, and the like. REMODEL also plays a role in cell-cell and cell-matrix adhesion, bone density, bone formation, dorsal closure, and is associated with spina bifida-like phenotype. The invention further relates to methods of treating and detecting these diseases, disorders or conditions, comprising modulating or detecting REMODEL expression and/or production of REMODEL polypeptide.

Abstract: The invention relates to novel nucleic acids encoding a mammalian adventitia inducible and bone expressed gene designated REMODEL, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, negative remodeling, arterial restenosis, vessel injury, ectopic ossification, fibrosis, and the like. REMODEL also plays a role in cell-cell and cell-matrix adhesion, bone density, bone formation, dorsal closure, and is associated with spina bifida-like phenotype. The invention further relates to methods of treating and detecting these diseases, disorders or conditions, comprising modulating or detecting REMODEL expression and/or production of REMODEL polypeptide.

Abstract: The invention relates to novel nucleic acids encoding a mammalian adventitia inducible and bone expressed gene designated REMODEL, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, negative remodeling, arterial restenosis, vessel injury, ectopic ossification, fibrosis, and the like. REMODELIN also plays a role in cell-cell and cell-matrix adhesion, bone density, bone formation, dorsal closure, bone mineralization, calcification/ossification, and is associated with spina bifida-like phenotype. In addition, the invention relates to affecting REMODELIN expression by administration of TGF-&bgr; and control of cellular gene expression using REMODELIN. The invention further relates to methods of treating and detecting these diseases, disorders or conditions, comprising modulating or detecting REMODELIN expression and/or production of REMODELIN polypeptide.

Abstract: Methods for inhibiting vascular stenosis in a mammal, including restenosis following surgical removal of atherosclerotic plaques. Inhibition is achieved through the administration of anti-growth factor antibodies, including anti-FGF antibodies and anti-PDGF antibodies.